Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gastric Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 155 articles: HTML format

Single Articles

October 2024
1. FU CK, Chien WC, Chen YJ, Yang MD, et al
   Impacts of Matrix Metalloproteinase-8 Genotypes, Smoking, Alcohol Drinking, and Helicobacter Pylori Infection on Gastric Cancer.
   Anticancer Res. 2024;44:4225-4232.
   PubMed     Abstract available
   
   
   
2. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
   Clinical Significance of Granzyme B Gene Expression in Pathological Stage II/III Gastric Cancer After Curative Gastrectomy.
   Anticancer Res. 2024;44:4537-4542.
   PubMed     Abstract available
   
   
   
3. BYEON SJ, Chang MS, Park HE, Kang D, et al
   Predictive Biomarkers of Lymph Node Metastasis in Early Gastric Cancer: A Reference of Clinicopathological Characteristics, Protein Expression, Epstein-Barr Virus Status, and Microsatellite Instability.
   Anticancer Res. 2024;44:4435-4448.
   PubMed     Abstract available
   
   
   
4. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
   Clinical Significance of HRNR Expression in Patients With Stage II/III Gastric Cancer After Curative Gastrectomy.
   Anticancer Res. 2024;44:4579-4584.
   PubMed     Abstract available
   
   
   September 2024
5. AOYAMA T, Maezawa Y, Hashimoto I
   Open, Laparoscopy-assisted, Robotic-assisted Distal Gastrectomy for Gastric Cancer: Evidence from Randomized Clinical Trials.
   Anticancer Res. 2024;44:3737-3745.
   PubMed     Abstract available
   
   
   
6. ARIGAMI T, Matsushita D, Shimonosono M, Hirase Y, et al
   Clinical Significance of Body Weight Loss During Chemotherapy for Advanced Gastric Cancer Undergoing Conversion Surgery.
   Anticancer Res. 2024;44:4031-4037.
   PubMed     Abstract available
   
   
   
7. HASHIMOTO I, Nakayama Y, Tanabe M, Morita J, et al
   Inflammatory Burden Index Prognostic Impact in Patients With Gastric Cancer After Gastrectomy: A Propensity Score-matched Analysis.
   Anticancer Res. 2024;44:3995-4001.
   PubMed     Abstract available
   
   
   August 2024
8. HASHIMOTO I, Komori K, Onuma S, Watanabe H, et al
   Preoperative Visceral-to-Subcutaneous Fat Ratio by Sex as a Predictor of Postoperative Survival in Patients With Gastric Cancer.
   Anticancer Res. 2024;44:3515-3524.
   PubMed     Abstract available
   
   
   July 2024
9. SATO Y, Yamashita H, Yagi K, Nomura S, et al
   Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial.
   Anticancer Res. 2024;44:3125-3131.
   PubMed     Abstract available
   
   
   June 2024
10. TAKAHASHI N, Fujisaki M, Takano Y, Takeshita K, et al
    New Proposal Strategy of Sentinel Lymph Node Navigation Surgery for Endoscopic Curability C-2: A Retrospective Study.
    Anticancer Res. 2024;44:2717-2724.
    PubMed     Abstract available
    
    
    
11. LI Y, Tazawa H, Nagai Y, Fujita S, et al
    Senescent Fibroblasts Potentiate Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells via IL-8-mediated Crosstalk.
    Anticancer Res. 2024;44:2497-2509.
    PubMed     Abstract available
    
    
    
12. PARK JW, Kim W, Kang HG, Kim WJ, et al
    DNA Hypermethylation Inhibits the CD82 Metastasis Suppressor Gene in Gastric Cancer.
    Anticancer Res. 2024;44:2459-2470.
    PubMed     Abstract available
    
    
    
13. KOMORI K, Yamada T, Ando S, Hashimoto I, et al
    Comparison of Survival Between ypStage and pStage in Gastric Cancer.
    Anticancer Res. 2024;44:2661-2670.
    PubMed     Abstract available
    
    
    May 2024
14. SUN SL, Sarofim M, Morris DL
    Transhepatic Bromelain and Acetylcysteine for Treatment of Posterior Gastric Pseudomyxoma Peritonei: A Case Report.
    Anticancer Res. 2024;44:2239-2241.
    PubMed     Abstract available
    
    
    
15. SHIROSAKI T, Kawai N, Ebihara Y, Murai A, et al
    Aldehyde Dehydrogenese-1 High Cancer Stem-like Cells/Cancer-initiating Cells Escape from Cytotoxic T Lymphocytes due to Lower Expression of Human Leukocyte Antigen Class 1.
    Anticancer Res. 2024;44:1877-1883.
    PubMed     Abstract available
    
    
    
16. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    The Clinical Impact of the Prognostic Immune and Nutritional Index in Gastric Cancer Patients Who Received Curative Treatment.
    Anticancer Res. 2024;44:2231-2238.
    PubMed     Abstract available
    
    
    
17. JUNG JY, Koh SA, Lee KH
    Cold-shock Domain Protein A (CSDA) Influences Hepatocyte Growth Factor-medicated Cell Proliferation and Metastasis in Gastric Cancer Cells.
    Anticancer Res. 2024;44:1973-1981.
    PubMed     Abstract available
    
    
    
18. KUM SJ, Jung YY, Kim HS
    Comparison of Clinicopathological and Prognostic Characteristics Between Minimal Deviation Adenocarcinoma and Gastric-type Endocervical Adenocarcinoma.
    Anticancer Res. 2024;44:2193-2204.
    PubMed     Abstract available
    
    
    April 2024
19. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    Clinical Impact of the Lymphocyte-to-Monocyte Ratio in Patients With Gastric Cancer who Received Curative Treatment.
    Anticancer Res. 2024;44:1567-1574.
    PubMed     Abstract available
    
    
    
20. HWANG SH, Kim DJ
    Nomogram for Predicting Infectious Complications Following Curative Gastrectomy Using Clinical and Laboratory Parameters.
    Anticancer Res. 2024;44:1781-1790.
    PubMed     Abstract available
    
    
    
21. NUMAKURA S, Uozaki H
    Gastric Cancer With the Increased Nicotinamide N-methyltransferase-positive Stromal Cells Includes Unfavorable Prognosis-related Cancer-associated Fibroblasts.
    Anticancer Res. 2024;44:1653-1660.
    PubMed     Abstract available
    
    
    
22. MORINO K, Yamamoto M, Shimoike N, Iwasaki Y, et al
    Safety and Limitations of Laparoscopic Total Gastrectomy for Gastric Cancer: A Comparative Analysis of Short and Long-term Outcomes With Open Surgery.
    Anticancer Res. 2024;44:1759-1766.
    PubMed     Abstract available
    
    
    
23. AOYAMA T, Maezawa Y, Hashimoto I, Hara K, et al
    The CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for Gastric Cancer Patients who Receive Curative Treatment.
    Anticancer Res. 2024;44:1629-1636.
    PubMed     Abstract available
    
    
    
24. AGATSUMA Y, Nakanishi K, Tanaka C, Kanda M, et al
    Risk Factors for Long-term Body Weight Loss After Proximal Gastrectomy: A Retrospective Analysis.
    Anticancer Res. 2024;44:1645-1651.
    PubMed     Abstract available
    
    
    
25. CHEN G, Shang J, Feng X, Li M, et al
    Hsa_circTCF25 Facilitates Oncogenesis in Gastric Cancer Cells by Modulating miR-149 Expression.
    Anticancer Res. 2024;44:1475-1485.
    PubMed     Abstract available
    
    
    February 2024
26. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of Tryptophanyl-tRNA Synthetase 1 Gene Expression in Patients With Locally Advanced Gastric Cancer.
    Anticancer Res. 2024;44:673-678.
    PubMed     Abstract available
    
    
    
27. KONDO J, Yoshino S, Iida M, Takeda S, et al
    Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH.
    Anticancer Res. 2024;44:621-630.
    PubMed     Abstract available
    
    
    
28. TANABE M, Aoyama T, Nakazono M, Morita J, et al
    Comparison of Dietary Intake After Gastric Cancer Gastrectomy Between Patients With and Without Postoperative Surgical Complications.
    Anticancer Res. 2024;44:839-844.
    PubMed     Abstract available
    
    
    
29. MATSUMOTO T, Toya R, Shimohigashi Y, Yamaguchi K, et al
    Influence of Respiratory Motion on Dose Distribution in Gastric Mucosa-associated Lymphoid Tissue Lymphoma Radiotherapy.
    Anticancer Res. 2024;44:687-694.
    PubMed     Abstract available
    
    
    
30. TAKAHASHI N, Takano Y, Takeshita K, Toya N, et al
    Proctoring System Enables Safe Induction of Robotic Gastrectomy: Short-term Outcomes of the First 10 Cases.
    Anticancer Res. 2024;44:823-828.
    PubMed     Abstract available
    
    
    January 2024
31. ITO S, Kuramochi H, Serizawa A, Ota M, et al
    Long-term Results of a Phase II Study of Neoadjuvant SOX for Advanced Gastric Cancer.
    Anticancer Res. 2024;44:195-204.
    PubMed     Abstract available
    
    
    
32. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Asialoglycoprotein Receptor 2 Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection.
    Anticancer Res. 2024;44:397-402.
    PubMed     Abstract available
    
    
    
33. SHIMONOSONO M, Arigami T, Matsushita D, Tsuruda Y, et al
    Evaluation of Quality of Life and Prognosis of Gastric Cancer Patients After Laparoscopic Subtotal Gastrectomy.
    Anticancer Res. 2024;44:387-396.
    PubMed     Abstract available
    
    
    
34. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of Pregnancy Zone Protein Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection.
    Anticancer Res. 2024;44:369-374.
    PubMed     Abstract available
    
    
    
35. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of Chitinase-3-like Protein 1 Gene Expression in Patients With Locally Advanced Gastric Cancer.
    Anticancer Res. 2024;44:307-312.
    PubMed     Abstract available
    
    
    
36. MORITA J, Aoyama T, Nakazono M, Tanabe M, et al
    Dietary Intake After Surgery in Patients With Gastric Cancer Who Underwent Laparoscopic-assisted Versus Those Who Underwent Conventional Gastrectomy.
    Anticancer Res. 2024;44:409-415.
    PubMed     Abstract available
    
    
    December 2023
37. AOYAMA T, Maezawa Y, Hashimoto I, Hara K, et al
    The Clinical Influence of Geriatric Nutritional Risk Index in Patients With Gastric Cancer Who Receive Curative Treatment.
    Anticancer Res. 2023;43:5605-5612.
    PubMed     Abstract available
    
    
    
38. SATO S, Kunisaki C, Tamura Y, Yago A, et al
    Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601).
    Anticancer Res. 2023;43:5663-5670.
    PubMed     Abstract available
    
    
    
39. MUKOYAMA T, Kanaji S, Sawada R, Harada H, et al
    Safety and Efficacy of Neoadjuvant Chemotherapy for Advanced Gastric Cancer in Elderly Patients.
    Anticancer Res. 2023;43:5649-5656.
    PubMed     Abstract available
    
    
    November 2023
40. OTSUKA R, Hayashi H, Uesato M, Hayano K, et al
    Inflammatory and Nutritional Indices as Prognostic Markers in Elderly Patients With Gastric Cancer.
    Anticancer Res. 2023;43:5261-5267.
    PubMed     Abstract available
    
    
    
41. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    The C-reactive Protein to Prealbumin Ratio Is an Independent Prognostic Factor for Patients With Gastric Cancer Who Receive Curative Surgery.
    Anticancer Res. 2023;43:5181-5187.
    PubMed     Abstract available
    
    
    
42. HORI N, Tazawa H, Li Y, Okura T, et al
    Intraperitoneal Administration of p53-armed Oncolytic Adenovirus Inhibits Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells.
    Anticancer Res. 2023;43:4809-4821.
    PubMed     Abstract available
    
    
    
43. SANO A, Sohda M, Hosoi N, Tateno K, et al
    Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
    Anticancer Res. 2023;43:5205-5213.
    PubMed     Abstract available
    
    
    
44. YAMAMOTO M, Omori T, Shinno N, Hara H, et al
    Adjuvant Chemotherapy With S-1 Plus Docetaxel Versus S-1 Plus Oxaliplatin in Stage III Gastric Cancer.
    Anticancer Res. 2023;43:5015-5024.
    PubMed     Abstract available
    
    
    
45. MATSUNAGA T, Satio H, Sakano YU, Makinoya M, et al
    Skeletal Muscle Mass Before Second-line Chemotherapy Correlates With Subsequent Prognosis and Rate of Late-line Chemotherapy in Patients With Unresectable Gastric Cancer.
    Anticancer Res. 2023;43:5051-5059.
    PubMed     Abstract available
    
    
    
46. KITAGAWA H, Hiraki M, Namba T, Baba K, et al
    The Oncological Effect of Mutant p53 on the Metastatic Phenotype of Gastric Cancer Cells.
    Anticancer Res. 2023;43:4887-4895.
    PubMed     Abstract available
    
    
    October 2023
47. TSUJIO G, Yashiro M, Sakuma T, Aoyama R, et al
    Impact of SMAD2 and MET Expression on Lymph Node Metastasis of HER2-positive Gastric Cancer Cells.
    Anticancer Res. 2023;43:4359-4364.
    PubMed     Abstract available
    
    
    
48. ZHANG YQ, Shi SS, Li YF, Yang Y, et al
    Melatonin Inhibits Gastric Cancer Cell Proliferation by Suppressing Exosome miR-27b-3p Expression.
    Anticancer Res. 2023;43:4413-4424.
    PubMed     Abstract available
    
    
    
49. DU L, Xie F, Han H, Zhang L, et al
    Targeting SALL4 by Entinostat Inhibits the Malignant Phenotype of Gastric Cancer Cells by Reducing EMT Signaling.
    Anticancer Res. 2023;43:4389-4401.
    PubMed     Abstract available
    
    
    September 2023
50. IWASAKI H, Haraguchi E, Ihashi T, Yokomizo H, et al
    Risk Factor of Sarcopenia After Gastrectomy in Elderly Patients With Gastric Cancer.
    Anticancer Res. 2023;43:4207-4212.
    PubMed     Abstract available
    
    
    August 2023
51. SHIMIZU S, Matsunaga T, Sawata S, Sakano YU, et al
    Preoperative Osteopenia Is a Risk Factor for Death in Patients Undergoing Gastrectomy for Gastric Cancer.
    Anticancer Res. 2023;43:3665-3672.
    PubMed     Abstract available
    
    
    
52. ENDO S, Yamada T, Kawada J, Higashida M, et al
    Proximal Resection Line Determination Using Intraoperative Radiography in Laparoscopic Distal Gastrectomy for Gastric Cancer.
    Anticancer Res. 2023;43:3685-3691.
    PubMed     Abstract available
    
    
    
53. TANAKA Y, Aoyagi K, Umetani Y, Tanaka YU, et al
    Impact of Skeletal Muscle Mass Reduction on Long-term Survival After Radical Resection of Gastric Cancer.
    Anticancer Res. 2023;43:3779-3786.
    PubMed     Abstract available
    
    
    July 2023
54. ARIGAMI T, Matsushita D, Shimonosono M, Tsuruda Y, et al
    Clinical Significance of Recurrence Risk Score for Conversion Surgery in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2023;43:3305-3310.
    PubMed     Abstract available
    
    
    
55. KANAJI S, Urakawa N, Mukoyama T, Harada H, et al
    Safety of Laparoscopic Gastrectomy for Advanced Gastric Cancer With Greater than Serosal Invasion Depth.
    Anticancer Res. 2023;43:3145-3152.
    PubMed     Abstract available
    
    
    
56. DAVAKIS S, Kapelouzou A, Sakellariou S, Kyriakoulis KG, et al
    Clinical and Oncological Impact of the Toll-like Receptor-3 and -4 in Esophageal and Gastro-esophageal Junction Adenocarcinoma.
    Anticancer Res. 2023;43:3183-3191.
    PubMed     Abstract available
    
    
    
57. WOLL E, Amann A, Eisterer W, Gerger A, et al
    Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy - An Update.
    Anticancer Res. 2023;43:2889-2897.
    PubMed     Abstract available
    
    
    June 2023
58. KOMORI K, Kano K, Ando S, Watanabe H, et al
    Clinicopathological Characteristics and Prognosis of Mucinous Gastric Cancer.
    Anticancer Res. 2023;43:2865-2871.
    PubMed     Abstract available
    
    
    
59. SIHOMBING AM, Murata S, Shimoji M, Miyake T, et al
    CD44-positive Cancer Stem-like Cells as a Potential Source of Peritoneal Metastasis After Surgery.
    Anticancer Res. 2023;43:2491-2500.
    PubMed     Abstract available
    
    
    
60. KASAHARA K, Kunisaki C, Sato S, Kondo H, et al
    Long-term Outcomes of Neoadjuvant Chemotherapy With Docetaxel, Cisplatin and S-1 for Stage III Gastric Cancer.
    Anticancer Res. 2023;43:2841-2850.
    PubMed     Abstract available
    
    
    
61. ITO E, Ogino I, Sugiura M, Watanabe S, et al
    Long-term Outcomes of Early-stage Non-stomach Gastrointestinal Mucosa-associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy.
    Anticancer Res. 2023;43:2851-2857.
    PubMed     Abstract available
    
    
    
62. HAYASHI K, Furuta M, Furusawa K, Hamaguchi T, et al
    Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
    Anticancer Res. 2023;43:2831-2840.
    PubMed     Abstract available
    
    
    May 2023
63. MIYAMOTO H, Yoshii M, Tanaka H, Nishi S, et al
    Dorsal Subcutaneous Fat Thickness as a Risk Factor for Pancreatic Fistula After Gastric Cancer Surgery.
    Anticancer Res. 2023;43:2171-2178.
    PubMed     Abstract available
    
    
    
64. ITO S, Ohgaki K, Kawazoe T, Sato S, et al
    Survival Benefits of Laparoscopic Gastrectomy in Elderly Patients With Gastric Cancer: Focusing on Preoperative Nutritional and Inflammatory Status.
    Anticancer Res. 2023;43:2055-2067.
    PubMed     Abstract available
    
    
    
65. YUKAWA N, Yamada T, Aoyama T, Woo T, et al
    Tumor DNA in Peritoneal Lavage as a Novel Biomarker for Predicting Peritoneal Recurrence in Patients With Gastric Cancer.
    Anticancer Res. 2023;43:2069-2076.
    PubMed     Abstract available
    
    
    
66. MORINO K, Yamamoto M, Yamanaka R, Iwasaki Y, et al
    Clinical Impact of Laparoscopic Surgery on the Long-term Survival of Advanced Gastric Cancer Patients With Regard to Facilitating Doublet Adjuvant Chemotherapy.
    Anticancer Res. 2023;43:2203-2209.
    PubMed     Abstract available
    
    
    April 2023
67. YANG YM, Ruge F, Ji KE, Jia S, et al
    ALCAM, Activated Leukocyte Cell Adhesion Molecule, in Clinical Gastric Cancer and Patient's Response to Chemotherapies.
    Anticancer Res. 2023;43:1463-1475.
    PubMed     Abstract available
    
    
    
68. OTSUKA R, Morishita H, Iida K, Hayano K, et al
    Serum Versus Tissue SIRT1 as Potentially Valuable Biomarkers in Gastric Cancer.
    Anticancer Res. 2023;43:1485-1491.
    PubMed     Abstract available
    
    
    
69. HASHIMOTO I, Kano K, Onuma S, Suematsu H, et al
    Clinical Significance of Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients With Metastatic Gastric or Gastroesophageal Junction Cancer Administered Trifluridine/Tipiracil.
    Anticancer Res. 2023;43:1689-1697.
    PubMed     Abstract available
    
    
    
70. AYUB A, Naeem B, Perez A, Tyler D, et al
    Gastric Linitis Plastica: Clinical Characteristics and Outcomes from the National Cancer Database.
    Anticancer Res. 2023;43:1543-1548.
    PubMed     Abstract available
    
    
    February 2023
71. AOYAMA T, Hara K, Maezawa Y, Kazama K, et al
    Clinical Course of Vitamin B12 Deficiency and Associated Risk Factors in Patients After Total Gastrectomy for Gastric Cancer.
    Anticancer Res. 2023;43:689-694.
    PubMed     Abstract available
    
    
    
72. UEHARA H, Ota M, Yamamoto M, Nakanoko T, et al
    Prognostic Significance of Preoperative Nutritional Assessment in Elderly Patients who Underwent Laparoscopic Gastrectomy for Stage I-III Gastric Cancer.
    Anticancer Res. 2023;43:893-901.
    PubMed     Abstract available
    
    
    
73. SHIBAMOTO J, Kubota T, Nishibeppu K, Ohashi T, et al
    Clinical Relevance of Proximal Gastrectomy With Double-flap Esophagogastrostomy Reconstruction With Glycemic Profile and Postgastrectomy Syndromes.
    Anticancer Res. 2023;43:857-864.
    PubMed     Abstract available
    
    
    
74. NAKAZAWA N, Sohda M, Tateno K, Watanabe T, et al
    Examining the Efficacy of Nivolumab for Gastric Cancer Focusing on Using an Inflammation-based Prognostic Score: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:927-934.
    PubMed     Abstract available
    
    
    
75. YAMAMOTO A, Shoda K, Kawaguchi Y, Akaike H, et al
    The Prognostic Implications of Perioperative Serum Cholesterol Levels in Patients With Gastric Cancer.
    Anticancer Res. 2023;43:903-909.
    PubMed     Abstract available
    
    
    January 2023
76. NAMIKAWA T, Utsunomiya M, Yokota K, Munekage M, et al
    Staple Line Reinforcement for Intracorporeal Anastomosis Reduces Time for Reconstruction During Laparoscopic Gastrectomy for Gastric Cancer.
    Anticancer Res. 2023;43:175-181.
    PubMed     Abstract available
    
    
    
77. HU Y, Huang L, Zhao K, Li Y, et al
    CTHRC1 Is Associated With Immune Escape and Poor Prognosis in Gastric Cancer.
    Anticancer Res. 2023;43:115-126.
    PubMed     Abstract available
    
    
    
78. KUWADA K, Kikuchi S, Kuroda S, Yoshida R, et al
    Survival Impact of Postoperative Skeletal Muscle Loss in Gastric Cancer Patients Who Underwent Gastrectomy.
    Anticancer Res. 2023;43:223-230.
    PubMed     Abstract available
    
    
    December 2022
79. SUEMATSU H, Sakamaki K, Oue N, Hiroshima Y, et al
    Clinical Significance of SEC11A Expression in Patients With Locally Advanced Gastric Cancer.
    Anticancer Res. 2022;42:5885-5890.
    PubMed     Abstract available
    
    
    
80. SAKAGUCHI M, Hosogi H, Hisamori S, Kinjo Y, et al
    Limited Oncological Benefits of Laparoscopic Total Gastrectomy With Splenectomy for Patients With Type 4 or Large Type 3 Gastric Cancer.
    Anticancer Res. 2022;42:5937-5944.
    PubMed     Abstract available
    
    
    
81. SUGEZAWA K, Morimoto M, Yamamoto M, Matsumi Y, et al
    GPX4 Regulates Tumor Cell Proliferation via Suppressing Ferroptosis and Exhibits Prognostic Significance in Gastric Cancer.
    Anticancer Res. 2022;42:5719-5729.
    PubMed     Abstract available
    
    
    November 2022
82. AOYAMA T, Hara K, Kazama K, Maezawa Y, et al
    Clinical Impact of Nutrition and Inflammation Assessment Tools in Gastric Cancer Treatment.
    Anticancer Res. 2022;42:5167-5180.
    PubMed     Abstract available
    
    
    
83. SERA T, Sakuma T, Maruo K, Tsujio G, et al
    Candidate Oncogenes, ARHGAP4, NOS3, and OR51B5, for the Development of Scirrhous-type Gastric Cancer.
    Anticancer Res. 2022;42:5195-5203.
    PubMed     Abstract available
    
    
    
84. KOMATSU M, Kinoshita T, Akimoto E, Yoshida M, et al
    The Significance of Staging Laparoscopy in Detection of Radiologically Occult Peritoneal Carcinomatosis in Gastric Cancer With Gastric Outlet Obstruction: Consideration of The Optimal Treatment Approach.
    Anticancer Res. 2022;42:5571-5578.
    PubMed     Abstract available
    
    
    October 2022
85. MATSUI R, Inaki N, Tsuji T, Fukunaga T, et al
    Relationship Between Fat Mass Indices and Postoperative Complications After Laparoscopic Gastrectomy in Patients With Gastric Cancer: A Propensity Score Matching Analysis.
    Anticancer Res. 2022;42:4841-4848.
    PubMed     Abstract available
    
    
    
86. MATSUOKA H, Mizuno T, Sakai M, Suzuki K, et al
    The Effect and Tolerability of Second-line Chemotherapy Are Associated With Disease Control by Nivolumab Chemotherapy in Patients With Gastric Cancer.
    Anticancer Res. 2022;42:4973-4980.
    PubMed     Abstract available
    
    
    
87. JANG H, Seo AN, Kim M
    Clinicopathological Characteristics of Advanced Epstein-Barr Virus-associated Gastric Cancer Highlighting Aberrant p53 Expression.
    Anticancer Res. 2022;42:4955-4962.
    PubMed     Abstract available
    
    
    September 2022
88. FUJII H, Sadaka S, Ajisawa K, Okumura N, et al
    Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2022;42:4581-4588.
    PubMed     Abstract available
    
    
    
89. MATSUI R, Inaki N, Tsuji T
    Impact of GLIM Defined Malnutrition on Long Term Prognosis in Patients With Gastric Cancer After Gastrectomy.
    Anticancer Res. 2022;42:4611-4618.
    PubMed     Abstract available
    
    
    
90. KOMORI K, Kano K, Aoyama T, Hara K, et al
    Clinical Impact of Surgical Sarcopenia on Long-term Survival.
    Anticancer Res. 2022;42:4545-4552.
    PubMed     Abstract available
    
    
    
91. PEREIRA BS, Wisnieski F, Calcagno DQ, Santos LC, et al
    Genetic and Transcriptional Analysis of 8q24.21 Cluster in Gastric Cancer.
    Anticancer Res. 2022;42:4381-4394.
    PubMed     Abstract available
    
    
    August 2022
92. JU M, Aoyama T, Komori K, Tamagawa H, et al
    The Albumin-Bilirubin Score Is a Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.
    Anticancer Res. 2022;42:3929-3935.
    PubMed     Abstract available
    
    
    
93. AOYAMA T, Maezawa Y, Cho H, Saigusa Y, et al
    Phase II Study of a Multi-center Randomized Controlled Trial to Evaluate Oral Vitamin B12 Treatment for Vitamin B12 Deficiency After Total Gastrectomy in Gastric Cancer Patients.
    Anticancer Res. 2022;42:3963-3970.
    PubMed     Abstract available
    
    
    
94. SUEMATSU H, Hashimoto I, Hiroshima Y, Watanabe H, et al
    Clinical Significance of EREG Gene Expression in Gastric Cancer Tissue After Curative Surgery.
    Anticancer Res. 2022;42:3873-3878.
    PubMed     Abstract available
    
    
    
95. KAKU H, Aoyagi K, Sudo T, Tanaka Y, et al
    Significance of Intraperitoneal-free KRT20 and CEACAM6 mRNA Expression for Peritoneal Recurrence of Gastric Cancer.
    Anticancer Res. 2022;42:4003-4010.
    PubMed     Abstract available
    
    
    July 2022
96. KIKUCHI S, Takata N, Kuroda S, Umeda H, et al
    Impact of Amino Acids Nutrition Following Gastrectomy in Gastric Cancer Patients.
    Anticancer Res. 2022;42:3637-3643.
    PubMed     Abstract available
    
    
    
97. TAKABATAKE K, Konishi H, Kubota T, Shiozaki A, et al
    Postoperative Nutrition Status of Patients With Esophago-gastric Junction Cancer With Gastric Tube or Esophago-gastric Reconstruction.
    Anticancer Res. 2022;42:3645-3652.
    PubMed     Abstract available
    
    
    June 2022
98. BOOKA E, Kikuchi H, Haneda R, Soneda W, et al
    Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
    Anticancer Res. 2022;42:2977-2987.
    PubMed     Abstract available
    
    
    
99. OH SE, Oh MY, Kim SM, Kim SY, et al
    Feasibility of Gastric Tumor Xenograft (GTX)-derived Cell Lines for Individualized Anti-cancer Drug Screening.
    Anticancer Res. 2022;42:2883-2891.
    PubMed     Abstract available
    
    
    May 2022
100. CHIN K, Takahari D, Kawabata R, Hosaka H, et al
     Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial.
     Anticancer Res. 2022;42:2683-2687.
     PubMed     Abstract available
     
     
     
101. KOMORI K, Kano K, Yamada T, Watanabe H, et al
     Usefulness of Surgical Staging of Gastric Cancer in Neoadjuvant Chemotherapy Candidates: A Single-center Retrospective Study.
     Anticancer Res. 2022;42:2719-2725.
     PubMed     Abstract available
     
     
     
102. VIRGILIO E, Montali F, Annicchiarico A, Salvemini C, et al
     Exosomal Functional Cargoes from Liquid Biopsy of Gastric Cancer: A Systematic Review of Studies With Potential Clinical Relevance.
     Anticancer Res. 2022;42:2249-2259.
     PubMed     Abstract available
     
     
     April 2022
103. HANAKI T, Sunaguchi T, Goto K, Morimoto M, et al
     The Significance of Surgical Intervention for Metasynchronous Liver Metastasis in Gastric Cancer: A Single-centre Analysis.
     Anticancer Res. 2022;42:2177-2184.
     PubMed     Abstract available
     
     
     
104. YOSHIOKA T, Takahashi M, Sakamoto Y, Okita A, et al
     Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial.
     Anticancer Res. 2022;42:2009-2015.
     PubMed     Abstract available
     
     
     
105. FU CK, Mong MC, Yu CC, Yang MD, et al
     Association of Matrix Metallopeptidase-2 Genotypes With Risk of Gastric Cancer in Taiwan.
     Anticancer Res. 2022;42:1749-1755.
     PubMed     Abstract available
     
     
     
106. ISHIKAWA A, Kuraoka K, Zaitsu J, Saito A, et al
     Transcriptomic Analysis of Annexin A10 and Chemosensitivity in Gastric Adenocarcinoma Cells.
     Anticancer Res. 2022;42:1707-1717.
     PubMed     Abstract available
     
     
     March 2022
107. MASUDA Y, Kananazawa Y, Matsuno K, Kakinuma D, et al
     Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab.
     Anticancer Res. 2022;42:1599-1605.
     PubMed     Abstract available
     
     
     
108. SUZUKI S, Urakawa N, Hasegawa H, Kanaji S, et al
     Prognostic Predictors After Surgical Intervention for Stage IV Gastric Cancer.
     Anticancer Res. 2022;42:1541-1546.
     PubMed     Abstract available
     
     
     
109. SUEMATSU H, Kano K, Yamada T, Hashimoto I, et al
     Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab.
     Anticancer Res. 2022;42:1535-1540.
     PubMed     Abstract available
     
     
     February 2022
110. URAKAWA N, Kanaji S, Suzuki S, Sawada R, et al
     Prognostic and Clinicopathological Significance of Lymph Node Metastasis in the Esophagogastric Junction Adenocarcinoma.
     Anticancer Res. 2022;42:1051-1057.
     PubMed     Abstract available
     
     
     January 2022
111. MOON SH, Park NS, Noh MH, Kim YS, et al
     Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells.
     Anticancer Res. 2022;42:555-563.
     PubMed     Abstract available
     
     
     
112. JUNG JY, Koh SA, Lee KH, Kim JR, et al
     14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion via Matrix Metalloproteinase-1 Regulation in Human Gastric Cancer.
     Anticancer Res. 2022;42:519-530.
     PubMed     Abstract available
     
     
     
113. KUSHIYAMA S, Yashiro M, Yamamoto Y, Sera T, et al
     Dipeptidyl Peptidase-4 from Cancer-associated Fibroblasts Stimulates the Proliferation of Scirrhous-type Gastric Cancer Cells.
     Anticancer Res. 2022;42:501-509.
     PubMed     Abstract available
     
     
     
114. TAKASHIMA Y, Komatsu S, Kasuga M, Ohashi T, et al
     Tumor Location on the Vertical Section of the Anterior Wall Is Related to Favorable Prognosis and Low Incidence of Lymph Node Metastasis in Lower-third Gastric Cancer.
     Anticancer Res. 2022;42:237-243.
     PubMed     Abstract available
     
     
     
115. AURELLO P, Minervini A, Pace M, D'Angelo F, et al
     The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review.
     Anticancer Res. 2022;42:25-33.
     PubMed     Abstract available
     
     
     
116. YANG JS, Kang CY, Su CH, Chen CJ, et al
     Helicobacter pylori Targets in AGS Human Gastric Adenocarcinoma: In Situ Proteomic Profiling and Systematic Analysis.
     Anticancer Res. 2022;42:531-546.
     PubMed     Abstract available
     
     
     
117. MIYATA H, Akiyama Y, Iizuka A, Kondou R, et al
     Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software.
     Anticancer Res. 2022;42:419-427.
     PubMed     Abstract available
     
     
     
118. QUESADA S, Samalin E, Thezenas S, Khellaf L, et al
     Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.
     Anticancer Res. 2022;42:185-193.
     PubMed     Abstract available
     
     
     November 2021
119. CHANG K, Song B, DO IG, Koo DH, et al
     Venous Invasion and Perineural Invasion as Upstaging and Poor Prognostic Factors in N0 Gastric Cancers.
     Anticancer Res. 2021;41:5803-5810.
     PubMed     Abstract available
     
     
     
120. OKUBO K, Arigami T, Matsushita D, Uenosono Y, et al
     The Clinical Significance of CA19-9 and Tumor Size Ratios for Predicting Prognosis After Conversion Surgery in Patients With Stage IV Gastric Cancer.
     Anticancer Res. 2021;41:5643-5649.
     PubMed     Abstract available
     
     
     
121. AOYAMA T, Nakazono M, Segami K, Nagasawa S, et al
     Safety and Feasibility of Gastrectomy for Gastric Cancer in Patients Receiving Antiplatelet and/or Anticoagulation Treatment.
     Anticancer Res. 2021;41:5605-5610.
     PubMed     Abstract available
     
     
     
122. MA YE, Liang X, Liu LI, Gao D, et al
     Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification.
     Anticancer Res. 2021;41:5507-5515.
     PubMed     Abstract available
     
     
     
123. TSUJIYA Y, Yamamori M, Hasegawa AI, Yamamoto Y, et al
     Telmisartan Exerts Cytotoxicity in Scirrhous Gastric Cancer Cells by Inducing G0/G1 Cell Cycle Arrest.
     Anticancer Res. 2021;41:5461-5468.
     PubMed     Abstract available
     
     
     September 2021
124. KOH SA, Lee KH
     HGF-mediated Up-regulation of PHLDA2 Is Associated With Apoptosis in Gastric Cancer.
     Anticancer Res. 2021;41:4377-4385.
     PubMed     Abstract available
     
     
     
125. CHEN HY, Yang MD, Chou YC, Ma YS, et al
     Ouabain Suppresses Cell Migration and Invasion in Human Gastric Cancer AGS Cells Through the Inhibition of MMP Signaling Pathways.
     Anticancer Res. 2021;41:4365-4375.
     PubMed     Abstract available
     
     
     
126. WEIDLE UH, Birzele F, Auslaender S, Brinkmann U, et al
     Down-regulated MicroRNAs in Gastric Carcinoma May Be Targets for Therapeutic Intervention and Replacement Therapy.
     Anticancer Res. 2021;41:4185-4202.
     PubMed     Abstract available
     
     
     August 2021
127. HAN SH, Han JH, Han SH, Kim HS, et al
     Fixation Using Carnoy's Solution Enables Detection of More Lymph Nodes After Gastrectomy for Gastric Cancer.
     Anticancer Res. 2021;41:3949-3953.
     PubMed     Abstract available
     
     
     
128. NAKAZAWA N, Sohda M, Yamaguchi A, Watanabe T, et al
     An Elevated Serum Lactate Dehydrogenase-to-albumin Ratio Is a Useful Poor Prognostic Predictor of Nivolumab in Patients With Gastric Cancer.
     Anticancer Res. 2021;41:3925-3931.
     PubMed     Abstract available
     
     
     
129. MATSUMOTO T, Toya R, Shimohigashi Y, Watakabe T, et al
     Plan Quality Comparisons Between 3D-CRT, IMRT, and VMAT Based on 4D-CT for Gastric MALT Lymphoma.
     Anticancer Res. 2021;41:3941-3947.
     PubMed     Abstract available
     
     
     July 2021
130. HYUN CL, Park SJ, Kim HS, Song HJ, et al
     The Intestinal Stem Cell Marker SMOC2 Is an Independent Prognostic Marker Associated With Better Survival in Gastric Cancer.
     Anticancer Res. 2021;41:3689-3698.
     PubMed     Abstract available
     
     
     
131. HATORI S, Sakamaki K, Yokohori T, Kimura Y, et al
     Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1.
     Anticancer Res. 2021;41:3583-3588.
     PubMed     Abstract available
     
     
     
132. KULIG P, Nowakowski P, Sierzega M, Pach R, et al
     Analysis of Prognostic Factors Affecting Short-term and Long-term Outcomes of Gastric Cancer Resection.
     Anticancer Res. 2021;41:3523-3534.
     PubMed     Abstract available
     
     
     
133. AKANDA MR, Park JS, Noh MG, Ha GH, et al
     TACC3 Promotes Gastric Carcinogenesis by Promoting Epithelial-mesenchymal Transition Through the ERK/Akt/cyclin D1 Signaling Pathway.
     Anticancer Res. 2021;41:3349-3361.
     PubMed     Abstract available
     
     
     
134. FU CK, Chang WS, Tsai CW, Wang YC, et al
     The Association of MMP9 Promoter Rs3918242 Genotype With Gastric Cancer.
     Anticancer Res. 2021;41:3309-3315.
     PubMed     Abstract available
     
     
     June 2021
135. ARIGAMI T, Matsushita D, Okubo K, Sasaki K, et al
     Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis.
     Anticancer Res. 2021;41:3099-3107.
     PubMed     Abstract available
     
     
     May 2021
136. TSAI CY, Liu KH, Chiu CT, Hsueh SW, et al
     Alpha-fetoprotein for Gastric Cancer Staging: An Essential or Redundant Tumor Marker?
     Anticancer Res. 2021;41:2711-2718.
     PubMed     Abstract available
     
     
     
137. TAKAO K, Konishi H, Matsubara D, Shoda K, et al
     MiR-3663-3p Inhibits the Progression of Gastric Cancer Through the CCND1 Pathway.
     Anticancer Res. 2021;41:2441-2449.
     PubMed     Abstract available
     
     
     April 2021
138. JIN YZ, Gong YX, Liu Y, Xie DP, et al
     Peroxiredoxin V Silencing Elevates Susceptibility to Doxorubicin-induced Cell Apoptosis via ROS-dependent Mitochondrial Dysfunction in AGS Gastric Cancer Cells.
     Anticancer Res. 2021;41:1831-1840.
     PubMed     Abstract available
     
     
     March 2021
139. NAKANISHI Y, Hirota S, Hojo Y, Nakamura T, et al
     Pathological Complete Remission of Liver Metastases Correlates With Elimination of Tumor-infiltrating Tregs in Gastric Cancer.
     Anticancer Res. 2021;41:1571-1577.
     PubMed     Abstract available
     
     
     
140. ZHANG X, Yamamoto Y, Wang X, Sato M, et al
     MDM4 as a Prognostic Factor for Patients With Gastric Cancer With Low Expression of p53.
     Anticancer Res. 2021;41:1475-1483.
     PubMed     Abstract available
     
     
     February 2021
141. SHIMODA Y, Fujikawa H, Komori K, Watanabe H, et al
     Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery.
     Anticancer Res. 2021;41:1005-1012.
     PubMed     Abstract available
     
     
     
142. SUZUKI O, Yamaguchi T, Fukuchi M, Mochiki E, et al
     Prediction Model for Gastric Cancer With DNA Mismatch Repair Deficiency.
     Anticancer Res. 2021;41:975-982.
     PubMed     Abstract available
     
     
     
143. SASAHARA M, Kanda M, Shimizu D, Tanaka C, et al
     Tissue RNFT2 Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer.
     Anticancer Res. 2021;41:609-617.
     PubMed     Abstract available
     
     
     January 2021
144. KIM EJ, Kim M, Seo S, Kim MJ, et al
     Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Versus Capecitabine/oxaliplatin.
     Anticancer Res. 2021;41:391-402.
     PubMed     Abstract available
     
     
     
145. LIM SC, Lee TB, Kang BS, Iy Han S, et al
     Extracellular Acidity-mediated Expression of cPLA2gamma Confers Resistance in Gastric Cancer Cells.
     Anticancer Res. 2021;41:211-218.
     PubMed     Abstract available
     
     
     
146. LEE GH, Park JW, Roh J, Kim YB, et al
     Association Between Waiting Time from Diagnosis to Endoscopic Submucosal Dissection and Non-curative Resection in Gastric Neoplasm.
     Anticancer Res. 2021;41:459-466.
     PubMed     Abstract available
     
     
     December 2020
147. FUJII H, Makiyama A, Iihara H, Okumura N, et al
     Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer.
     Anticancer Res. 2020;40:7067-7075.
     PubMed     Abstract available
     
     
     
148. NAKAMURA S, Kanda M, Shimizu D, Tanaka C, et al
     AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer.
     Anticancer Res. 2020;40:6713-6721.
     PubMed     Abstract available
     
     
     November 2020
149. TRUMBULL D, Lemini R, Attwood K, Kukar M, et al
     Gastric Cancer Disparities Among Asian American Subpopulations.
     Anticancer Res. 2020;40:6381-6385.
     PubMed     Abstract available
     
     
     
150. CHEN YC, Wu CC, Tu YT, Chen YR, et al
     Involvement of the MicroRNA-1-LITAF Axis in Gastric Cancer Cell Growth and Invasion.
     Anticancer Res. 2020;40:6247-6256.
     PubMed     Abstract available
     
     
     
151. MAKI M, SOderstrOm D, Paloheimo L, Hendolin P, et al
     Helicobacter pylori (Hp) IgG ELISA of the New-Generation GastroPanel(R) Is Highly Accurate in Diagnosis of Hp-Infection in Gastroscopy Referral Patients.
     Anticancer Res. 2020;40:6387-6398.
     PubMed     Abstract available
     
     
     October 2020
152. HASHIMOTO I, Oue N, Kimura Y, Hiroshima Y, et al
     Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.
     Anticancer Res. 2020;40:5815-5821.
     PubMed     Abstract available
     
     
     
153. ENDO S, Fujiwara Y, Yamatsuji T, Nishikawa K, et al
     Is it Necessary to Confirm Negative Margins in Gastrectomy for Peritoneal Lavage Cytology-positive Gastric Cancer?
     Anticancer Res. 2020;40:5807-5813.
     PubMed     Abstract available
     
     
     
154. UEJIMA C, Morimoto M, Yamamoto M, Hara K, et al
     Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer.
     Anticancer Res. 2020;40:5593-5600.
     PubMed     Abstract available
     
     
     
155. SUGISAWA N, Nishino H, Higuchi T, Park JH, et al
     A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
     Anticancer Res. 2020;40:5393-5397.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.